This trial is active, not recruiting.

Conditions hypophosphatemia, familial, rickets, hyperphosphatemia
Treatments alfacalcidol; phosphate., sevelamer
Sponsor Haukeland University Hospital
Start date December 2009
End date December 2018
Trial size 80 participants
Trial identifier NCT01057186, 21922


The purpose of the study is to do a follow-up survey of all individuals with hereditary hypophosphatemia in Norway, focusing on manifestations in childhood and adolescence. The investigators also want to study phenotype-genotype associations, and look for new genes, in all forms of hereditary hypo and hyperphosphatemia.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Norwegian patients with hereditary hypophosphatemia.
alfacalcidol; phosphate.
Individual dosage form and dosage depending on phenotype and underlying cause.
Norwegian patients with hereditary hyperphosphatemia (hyperphosphatemic familial tumoral calcinosis and hyperphosphatemia hyperostosis syndrome).
Pills. Individual dosage depending on clinical symptoms/phenotype.

Primary Outcomes

time frame: Up to 18 years

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - All patients in the Norwegian population with hereditary hypophosphatemia, with or without rickets - Patients in the Norwegian population with hereditary hyperphosphatemia Exclusion Criteria:

Additional Information

Official title Hypophosphatemic Rickets in Norway
Trial information was received from ClinicalTrials.gov and was last updated in August 2016.
Information provided to ClinicalTrials.gov by Haukeland University Hospital.